PMC8474249_01
(A, B) Fused FDG PET/CT axial images of the baseline scan (lung window) illustrating metabolically active soft tissue mass lesion in the upper lobe of the right lung. (C, D) Fused FDG PET/CT scan axial images after three cycles of chemotherapy (lung window) exhibiting an increase in the metabolic activity of the mass lesion in the upper lobe of the right lung, along with an increase in the size, number, and metabolic activity of the bilateral lung nodules. (E, F) Fused FDG PET/CT scan axial images after the start of osimertinib treatment (lung window) illustrating a decrease in size and metabolic activity of the mass lesion in the upper lobe of the right lung along with a considerable decrease in the size, number, and metabolic activity of bilateral lung nodules. CT, computed tomography; FDG, fluorodeoxyglucose; PET, positron emission tomography.
gr1.jpg
PMC8474249_01_gr1.jpg
fig1
A 39-year-old male patient, never-smoker, with a long-term cough was diagnosed as having a lung mass through endobronchial ultrasound and bronchoscopy, which revealed a solid pattern of adenocarcinoma with paratracheal lymph node involvement (Fig. 1A and B) depicting small-cell carcinoma along with multiple liver, bone, and brain metastases. Re-evaluation with positron emission tomography-computed tomography was suggestive of progressive disease. (Fig. 1C and D). He was started on osimertinib in February 2020, and re-evaluation in May 2020 revealed partial response (Figs. 1E and F) to treatment.